[go: up one dir, main page]

MX9305453A - Metodo para tratar infecciones virales. - Google Patents

Metodo para tratar infecciones virales.

Info

Publication number
MX9305453A
MX9305453A MX9305453A MX9305453A MX9305453A MX 9305453 A MX9305453 A MX 9305453A MX 9305453 A MX9305453 A MX 9305453A MX 9305453 A MX9305453 A MX 9305453A MX 9305453 A MX9305453 A MX 9305453A
Authority
MX
Mexico
Prior art keywords
viral infections
treating viral
oso3
responds
substance
Prior art date
Application number
MX9305453A
Other languages
English (en)
Inventor
Carl Franz De Vos Albrecht
Roelof Wilkw Liebenberg
Petrus Bys Kruger
Patrick Jacques Desire Bouic
Original Assignee
Virostat Na Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virostat Na Nv filed Critical Virostat Na Nv
Publication of MX9305453A publication Critical patent/MX9305453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere con la preparación de una sustancia para el tratamiento de infecciones virales que responde a la fórmula general (1): en donde R1, R2, R3, Y R4, son iguales o diferentes entre sí y se seleccionan entre -H, -OH, A, B, C, Y D, donde : cualquiera de los 1-3 de los grupos -OSO3 está sustituido opcionalmente con -OH.
MX9305453A 1992-09-07 1993-09-06 Metodo para tratar infecciones virales. MX9305453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA926775 1992-09-07
ZA933949 1993-06-04

Publications (1)

Publication Number Publication Date
MX9305453A true MX9305453A (es) 1994-05-31

Family

ID=66817979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305453A MX9305453A (es) 1992-09-07 1993-09-06 Metodo para tratar infecciones virales.

Country Status (10)

Country Link
EP (1) EP0587396A1 (es)
JP (1) JPH06219974A (es)
KR (1) KR940006591A (es)
CN (1) CN1091291A (es)
AU (1) AU667564B2 (es)
BR (1) BR9303733A (es)
CA (1) CA2105630A1 (es)
IL (1) IL106939A0 (es)
MX (1) MX9305453A (es)
ZW (1) ZW11693A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569649A (en) * 1994-06-14 1996-10-29 Phytopharm (Na) N.V. Anti-inflammatory treatment method
SG11201404361UA (en) * 2012-01-26 2014-09-26 Life Technologies Corp Methods for increasing the infectivity of viruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2120650A (en) * 1982-04-19 1983-12-07 Roecar Holdings Nv Rooperol derivatives
GB8317850D0 (en) * 1983-06-30 1983-08-03 Roecar Holdings Nv Rooperol and its derivatives
ATE61329T1 (de) * 1985-06-19 1991-03-15 Rooperol Na Nv Verfahren zur herstellung von rooperol, hypoxosid und deren derivaten.

Also Published As

Publication number Publication date
AU4611093A (en) 1994-03-17
AU667564B2 (en) 1996-03-28
CN1091291A (zh) 1994-08-31
KR940006591A (ko) 1994-04-25
JPH06219974A (ja) 1994-08-09
IL106939A0 (en) 1993-12-28
BR9303733A (pt) 1994-03-15
EP0587396A1 (en) 1994-03-16
CA2105630A1 (en) 1994-03-08
ZW11693A1 (en) 1994-03-30

Similar Documents

Publication Publication Date Title
ATE269290T1 (de) Benzoylderivate
DE69200685D1 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten.
ES2134926T3 (es) Derivados vinileno-azaindolicos y su procedimiento de preparacion.
DK249389D0 (da) 2-acylamino-benzothiazol-forbindelser og deres anvendelse til fremstilling af laegemidler til behandling af tumorer
DE3576328D1 (de) Behandlung feuerfester gegenstaende.
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
ES2052961T3 (es) Compuestos de fosfonio con actividad biocida.
ES2156120T3 (es) Derivados arilamidicos.
PT100357A (pt) Compostos lactama macrociclicos, seu processo de preparacao e intermediarios, e composicoes que os contem
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
ES2157899T3 (es) Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
ATE61044T1 (de) Insektizide n-(gegebenenfalls substituierte)-n'substituierte-n,n'-disubstituierte hydrazine.
MX9305453A (es) Metodo para tratar infecciones virales.
SE8302751L (sv) 2(1h)-pyridinonderivat, deras framstellning och farmaceutiska beredningar som innehaller dem
MX9301863A (es) Morfolin y tiomorfolin 4-ilamidas
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.
ATE147628T1 (de) Iloprost mit wirkung gegen cerebrale malaria
ES2059396T3 (es) Derivados de indeno y metodos.
NO175856C (no) Analogifremgangsmåte for fremstilling av nye - og fucosidase-inhibitorer
MX9300008A (es) Nucleosidos terapeuticos.
ES2095431T3 (es) N-(isoquinolein-5-il)-sulfonil-azacicloalcanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2003063A4 (es) Derivados de pirrolidin-2-ona, que tengan actividad nootropica.
FI915801A0 (fi) Komposition och foerfarande foer att foerhindra fluoros.
ES2055700T3 (es) Mezclas bactericidas.
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.